N/A N=66 Tai Chi Mind-Body Therapy for Fibromyalgia
Fibromyalgia
Primary: Mean Change From Baseline of Fibromyalgia Impact Questionnaire Score — -27.8; -9.4 units on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=58 Drug and Talk Therapy for Fibromyalgia
Fibromyalgia
Primary: Change in Weekly Average Pain Intensity — -2.1; -0.97; -1.67 units on a scale
N/A N=43 Transcutaneous Electrical Nerve Stimulation (TENS) and Fibromyalgia (FM)
Fibromyalgia
Primary: Pain at Rest Difference Score Pre-intervention and Post Intervention — 0.38; -0.74; -0.47 units on a scale
N/A N=9 Virtual Reality and Meditation for Fibromyalgia
Fibromyalgia
Primary: Pain Numerical Rating Scale [NRS] (Change From Pre-intervention to Post-intervention) — 4.4; 4.8 score on a scale
Phase 4 N=22 A Study to Evaluate the Effects of Milnacipran on Pain Processing and Functional MRI in Patients With Fibromyalgia
Fibromyalgia
Primary: Pain Threshold at Baseline — 2.7333; 2.583 kg/cm^2
N/A N=57 Light Treatment to Improve Symptom Management of Fibromyalgia Syndrome
Fibromyalgia · FMS
Primary: Fibromyalgia Impact Questionnaire, Revised (FIQ-R) Score — 40.8; 45.3; 38.0; 39.4 score on a scale — p=0.28
Phase 1 N=27 An fMRI Study Of Brain Response In Patients With Fibromyalgia
Fibromyalgia
Primary: Glutamine/Creatine (Gln/Cr) and Glutamate/Creatine (Glu/Cr) Ratios Measured by Proton Magnetic Resonance Spectroscopy (1H-MRS) — 1.1751; 1.13253; 1.1046; 1.17129 ratio…
N/A N=301 Fibromyalgia Activity Study With Transcutaneous Electrical Nerve Stimulation (FAST)
Fibromyalgia
Primary: Pain Rating With Movement (0-10 Low to High Scale) During Six Minute Walk Test — -1.8; -0.8; 0.00; -2.0 Units on a scale — p=0.008
N/A N=20 Repetitive Transcranial Magnetic Stimulation (rTMS) in Fibromyalgia
Fibromyalgia
Primary: Visual Analog Scale-Pain — 5.30; 6.80 units on a scale
Phase 2 N=56 Neurotropin Treatment of Fibromyalgia
Fibromyalgia
Primary: Fibromyalgia Impact Questionnaire — 49.9; 37.5; 39.9; 33.4 units on a scale
N/A N=91 The Clinical Effect of Low-Intensity Electromagnetic Field Neurostimulation in Fibromyalgia Syndrome Patients
Fibromyalgia
Primary: Change in Tender Point Pain Threshold — 19.6; -3.2 units on a scale
Phase 3 N=114 Coping Skills Training for Adolescents With Fibromyalgia
Fibromyalgia
Primary: Change in FDI (Functional Disability Inventory) Scores at End of Study — 21.4; 19.2; 13.4; 17.0 units on a 0-60 scale — p=0.007
Phase 3 N=343 A Study For Pregabalin In Patients With Fibromyalgia
Fibromyalgia
Primary: Change From Baseline in Endpoint Mean Pain Score During the Double-blind Treatment Period at Week 14 — -2.01; -1.28 Units on a scale — p=0.0001
Phase 3 N=393 A Study of Duloxetine in Fibromyalgia
Fibromyalgia
Primary: Change From Baseline to 14-Week Endpoint in the BPI 24-Hour Average Pain Severity Item of the BPI-Modified Short Form Score (MMRM) — -1.90; -1.58 units on a scale…
N/A N=317 Fibromyalgia Integrative Training for Adolescents With Juvenile Fibromyalgia
Fibromyalgia · Myofascial Pain Syndrome · Muscular Diseases
Primary: Functional Disability Inventory — 25.78; 24.10; 25.96; 21.83 score on a scale
N/A N=84 Lifestyle Physical Activity to Reduce Pain and Fatigue in Adults With Fibromyalgia
Fibromyalgia
Primary: Ambulatory Pain (Higher Values Indicate Greater Pain) — 54.6; 58.9; 46.3; 62.4 units on a scale
Phase 4 N=308 A Study for Adult Patients With Fibromyalgia
Fibromyalgia, Primary · Fibromyalgia, Secondary
Primary: Change From Baseline to 12-Week Endpoint in the Brief Pain Inventory (BPI) "24-Hour Average Pain" Item (Question 3) of the BPI-Modified Short Form Score — -2.04; -1.70…
Phase 4 N=19 The Effects of Milnacipran on Sleep Disturbance in Fibromyalgia
Sleep Disorders · Fibromyalgia · Sleep
Primary: Number of Awakenings After Sleep Onset (NAASO) — 39.5; 34.9 Awakenings — p=0.424
N/A N=110 Probiotic VSL#3 for the Treatment of Gastrointestinal Symptoms Associated to Fibromyalgia
Fibromyalgia · Gastrointestinal Disease
Primary: Change, From Baseline to Endpoint (12 Weeks) in the Composite Score of Abdominal Pain, Abdominal Bloating and Metheorism Each One Measured in a 0-10 Visual Analog Scale…
Phase 2 N=46 Effectiveness of Acupuncture in Relieving Pain Due to Fibromyalgia
Fibromyalgia
Primary: Change in Mu-opioid Receptor Occupancy — 0.2352; .0015 Unitless: binding potential is Bmax/Kd
N/A N=40 Fibromyalgia Integrative Training for Teens
Juvenile Fibromyalgia
Primary: Average Pain Intensity — 6.26; 6.41; 4.69; 6.38 units on a scale — p=.011
N/A N=67 Physical Exercise and Its Impact on Signs of Inflammation in Fibromyalgia
Exercise Therapy · Pain
Primary: Six-minute Walk Test — 37.7; 8.6 meter
Phase 3 N=193 A Phase 3b Multicenter Study of Pregabalin in Fibromyalgia Subjects Who Have Comorbid Depression
Fibromyalgia
Primary: Mean NRS Pain Score at End of Period. — 4.84; 5.45 Units on a scale — p=0.0001
Phase 2 N=19 Dextromethorphan in Fibromyalgia
Fibromyalgia
Primary: Daily Self-reported Pain Severity — 41.09; 45.55 score/day — p=0.146
Phase 2 N=7 Open-label Study to Assess the Safety and Efficacy of Psilocybin With Psychotherapy in Adult Participants With Fibromyalgia
Fibromyalgia
Primary: Heart Rate Beats Per Minute (BPM) - First Dose (15 mg) — 76; 67; 67; 68 Heart beats per minute
Phase 2 N=14 The Effect of Minocycline and N-acetylcysteine for the Treatment of Fibromyalgia
Fibromyalgia
Primary: Change in Revised Fibromyalgia Impact Questionnaire (FIQR) Score From Baseline to After Treatment Occurring at Weeks 8 and 18 — 4.37; 12.1 Score
Phase 2 N=67 "SMART-FM": Smart-Phone Based Digital Therapeutic for Management of Fibromyalgia
Fibromyalgia
Primary: Revised Fibromyalgia Impact Questionnaire (FIQ-R) Total Score — -8.7; -3.0 score on a scale
Phase 3 N=6 Safety and Efficacy of Fluoxetine in Juvenile Fibromyalgia
Juvenile Primary Fibromyalgia Syndrome (JPFS) · Fibromyalgia
Primary: Average Pain Severity Score — 62 mm
Phase 3 N=113 Growth Hormone in Neuroendocrine Dysfunction With Severe Fibromyalgia Syndrome
Fibromyalgia
Primary: Percentage of Participants With Less Than 11 Tender Points at Month 6 — 20; 22 Percentage of participants
Phase 2 N=195 Trial Comparing the Effects of Xyrem (Sodium Oxybate) With Placebo for the Treatment of Fibromyalgia
Fibromyalgia
Primary: The Primary Outcome Measure Was a Composite of Changes From Baseline in Three Co-primary Self Report Measures: Pain Visual Analog Scale (PVAS, Electronic Diaries)…